Jennifer J.D. Morrissette, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Clinical Director, Center for Personalized Diagnostics
University of Pennsylvania Perelman School of Medicine
Contact InformationDepartment of Pathology and Laboratory Medicine
3020 Market Street, Suite 220
Philadelphia, PA 19104
Office: 215-898-5578
Fax: 215-898-9817
Email: jennifer.morrissette@uphs.upenn.edu
Specialty Division
Precision and Computational Diagnostics
Education
B.S. (Molecular Biology), State University of New York at Buffalo, 1986
Ph.D. (Molecular Genetics), State University of New York at Buffalo, 1992
Specialty Certification
American Board of Medical Genetics, Clinical Molecular Genetic Diagnostics, 2002
American Board of Medical Genetics, Clinical Cytogenetics, 2002
New York State Certificate of Qualification,
Cytogenetics and Molecular Genetic Diagnostics, 2004
Postgraduate Training
Postdoctoral Fellow, Molecular Genetics, Department of Pathology, Harvard Medical School, Boston MA, 1992-1997
Fellow in Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 1998-2002
Awards and Honors
Mark Diamond Initiative Award, Department of Biological Sciences, State University of New York at Buffalo, 1990
NIH Intramural Research Training Award fellowship, 1992-1993
Pathobiology of Cancer: The Edward A. Smuckler Memorial Workshop, Keystone Colorado, American Association of Cancer Research, 1992
American Social Health Association/Burroughs Wellcome Fund Research Fellowship, 1994-1996
American Association of Cancer Research Fellowship, 1996-1997
General Clinical Research Center (GCRC). Children’s Hospital of Philadelphia, Investigator, 2001-2005
Foerderer Fund for Excellence, Molecular and Cytogenetic Analysis of Autism, 2003-2004
Peter C. Nowell Award in Pathology, University of Pennsylvania, 2013
Memberships and Professional Organizations
American Society Human Genetics, 1998 - Present
Philadelphia Genetics Group, 2004 - 2018
American College of Medical Genetics, 2005 - Present
American Cytogenetics Conference, 2006 - Present
Association of Molecular Pathology, 2011 - Present
International Federation of Clinical Chemistry and Laboratory Medicine, 2019 - Present
Web Links
Selected Publications
Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.
Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S., Br J Cancer., 2019, PMID:30478409
FBXW7 mutations in acute myeloid leukemia.
Sadigh S, Morrissette JJD, Bagg A., Leuk Lymphoma. 11(): , 2019, PMID:30632836
Classes of ITD predict outcomes in AML patients treated with FLT3 inhibitors.
Schwartz GW, Manning BS, Zhou Y, Velu PD, Bigdeli A, Astles R, Lehman AW, Morrissette JJ, Perl AE, Li M, Carroll M, Faryabi RB., Clin Cancer Res., 2018, PMID:30181385
Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ., Clin Lymphoma Myeloma Leuk., 2018, PMID:30033208
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ., Nature, 2018, PMID:29849141
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ., JCO Precis Oncol., 2018, PMID:30766968
Validation of a next-generation sequencing oncology panel optimized for low input DNA.
Sussman RT, Shaffer S, Azzato EM, DeSloover D, Farooqi MS, Meyer A, Lieberman DB, Bigdeli A, Paolillo C, Ganapathy K, Sukhadia S, Rosenbaum JN, Daber RD, Morrissette JJD., Cancer Genet, 2018
In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.
Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C., Neuro Oncol., 2018, PMID:29617843
ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma.
Jenkins TM, Morrissette JJD, Kucharczuk JC, Deshpande CG., Int J Surg Pathol 26(): , 2018, PMID:29295663
Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.
Babushok DV, Nelson EJ, Morrissette JJD, Joshi S, Palmer MB, Frank D, Cambor CL, Hexner EO., Leuk Lymphoma., 2018, PMID:30227762
